Articles tagged with Drug Studies
A recent clinical trial found that semaglutide significantly reduced cardiovascular events in adults with overweight or obesity who do not have diabetes. The medication was shown to lower the risk of death from cardiovascular causes, nonfatal heart attacks, and strokes by 20% compared to placebo.
Researchers at the University of Illinois have developed a new antifungal molecule that targets fungal cells without harming human kidney cells or other tissues. The molecule, dubbed AM-2-19, has shown significant efficacy against various fungal infections in vitro and in vivo studies.
A study published in Nature Communications reveals that the 'salience network' in the brain is uniquely activated by intravenous drug use, which may be associated with higher addiction rates and faster relief from withdrawal. This finding could lead to the development of new therapies for substance use disorders.
Patients with HER2-positive breast cancer that has spread to other parts of the body survive for longer if treated with pyrotinib. The new drug targets proteins involved in HER2-positive breast cancer and shows a 22% reduction in risk of death compared to lapatinib.
A recent study found that transient inflammatory pain causes persistent mitochondrial and metabolic disturbances in sensory neurons, leading to failure in pain resolution. Targeting the cellular redox balance prevents and treats chronic inflammatory pain in rodents.
A new study has found that tumor necrosis factor inhibitors, commonly used for inflammatory arthritis, are not associated with poor pregnancy outcomes. Women who continued treatment had lower risks of severe infections postpartum compared to those who stopped. The results provide reassuring data on the use of TNF blockers during pregna...
A phase 1 trial of the radiopharmaceutical 225AC-J591 demonstrated promising antitumor activity against advanced metastatic prostate cancer, reducing PSA levels by at least half for 47% of patients. The treatment was well-tolerated, with only temporary low blood cell count side effects.
A small clinical trial led by the University of Houston demonstrates Riluzole's effectiveness in improving functionality in people with acute spinal cord injuries. The study used an SCI-specific biomarker to show how Riluzole reduces neuron cell damage and improves motor abilities.
A multicenter, retrospective study of Japanese patients treated with JAK inhibitors found impressive remission rates and low disease activity. The study's results contradict previous concerns about the effectiveness of these drugs, suggesting they may be a viable option for patients with other health problems.
Scientists at the University of Cambridge identified a molecule that plays a key role in triggering inflammation in response to harmful materials. The researchers found that inhibiting this molecule, PLK1, can prevent overly aggressive inflammatory responses in conditions like gout and heart diseases.
A large-scale study found that metformin can reduce weight gain and increase adherence to treatment in youth with bipolar disorder. The medication, typically used for Type 2 diabetes, was effective in preventing weight gain and showed promise as a potential solution to this common side effect of SGAs.
A new international clinical trial found that a drug candidate is highly effective in treating Acanthamoeba keratitis with medical cure rates of 87%, reducing the risk of poor visual outcomes and surgery. The treatment, low concentration polihexanide (PHMB 0.08%), follows a novel and evidence-based protocol.
A UCLA-led study shows datopotamab deruxtecan, a Trop-2 directed antibody-drug conjugate, significantly improves progression-free survival in patients with metastatic non-small cell lung cancer. The treatment primarily benefits patients with non-squamous tumors, reducing disease progression and improving overall survival.
A year-long clinical trial found sustained remission of polymyalgia rheumatica in 28% of patients taking sarilumab, compared to 10% of those on placebo. The treatment showed promise in reducing relapse and improving outcomes for patients tapering their steroid medication.
A brain-computer interface (BCI) has been successfully used to restore control of home devices for a patient with ALS, allowing the individual to navigate a communication board and smart devices without recalibration. The BCI device was implanted on the surface of the brain areas responsible for speech and upper limb function, enabling...
A global platform study has released results on the use of simvastatin to treat severely ill patients with COVID-19, showing a high probability of improving outcomes. In contrast, high-dose vitamin C was found to be ineffective and potentially harmful in critically ill patients, suggesting its use should be discontinued.
A clinical trial has shown that combining chemotherapy with immunotherapy nivolumab significantly improved outcomes in patients with advanced bladder cancer. The study found nearly twice as many patients with no evidence of disease after treatment, and a median complete response of 37.1 months.
A new drug, cabozantinib, has shown positive results in a clinical trial involving patients with advanced neuroendocrine tumors. The study found that patients treated with cabozantinib survived significantly longer without their disease worsening compared to those who received a placebo. This novel treatment strategy targets angiogenes...
A phase III pivotal trial evaluating cabozantinib in advanced neuroendocrine tumors demonstrated significant improvements in median progression-free survival (PFS) compared to placebo. The study met its primary objective for both cohorts of patients, providing encouraging news for those with progressive disease.
A new study found that muscle dysmorphia symptoms are associated with increased risk of suicidal thoughts and behaviors among Canadian adolescents and young adults. The study highlights the need for greater awareness and proper identification of muscle dysmorphia symptoms to prevent future suicidal ideation and suicide planning.
A new cancer immunotherapy that targets two immune-evading tumor tactics has shown promising results in an early clinical trial. The drug, tebotelimab, blocks both PD-1 and LAG-3 proteins, leading to a double-digit response rate in patients with advanced solid tumors or blood cancers.
Scientists have developed a technique to restore the function of human-derived GPCR proteins in yeast cells, which could accelerate research and lead to more effective treatments. The approach, using error-prone polymerase chain reaction, introduces random mutations that enhance protein stability and function.
A study published in Psychological Medicine found that the widely prescribed sedative alprazolam XR may be less effective than believed, with publication bias inflating its efficacy by over 40%. This suggests caution for patients and clinicians starting a prescription for panic disorder.
The study found that precision oncology therapies require genomic biomarker screening for patient selection and have expanded over the years. The analysis showed a slow expansion in approvals from 1998 to 2017 and a rapid increase from 2017 to 2022, with 86 out of 198 approved drugs classified as precision oncology drugs.
A phase 3 clinical trial demonstrated tirzepatide's effectiveness in achieving an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or overweight comorbidities. Participants who received tirzepatide achieved a total mean weight loss of 26.6%, compared to 3.8% for those on placebo.
The ATLANTIS trial found that amitriptyline significantly improved IBS symptoms, with participants taking the medication reporting a bigger improvement in symptom scores after six months. The medication was well-tolerated and showed no significant impact on anxiety or depression scores.
Researchers developed a nanotechnology method to deliver medication through the blood-brain barrier, overcoming its selectivity and expanding therapeutic options for glioblastoma treatment. The technique demonstrated improved tumor shrinkage and survival rates in mice, paving the way for further preclinical studies.
A new trial combining an Alzheimer's medication with two other drugs may amplify its effects and arrest disease progression. The trial, funded by a $150M grant, will recruit 900 participants with early-onset Alzheimer's.
A study by researchers from National Institutes of Health and Glasgow University found that amlodipine does not activate calcium channels, contradicting earlier concerns. The medication remains a recommended first-line treatment for high blood pressure, reducing deaths from hypertension.
TTUHSC researchers received funding for pilot studies on photothermal tumor therapy, clear cell renal cell carcinoma, and colorectal cancer screening in underserved areas. The grants support the purchase of a cell sorter and address regional health disparities.
Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.
A new study shows that XEN1101 can reduce seizure frequency by more than 50% in some patients and sometimes eliminate seizures altogether. The medication, a potassium-channel opener, boosts the flow of potassium out of nerves to stop them from firing.
A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.
A large epidemiological study found a higher incidence of stomach paralysis, pancreatitis, and bowel obstruction in patients taking GLP-1 agonist medications for weight loss. The study, published in JAMA, highlights the need for updated warning labels to inform patients of these potential risks.
A Phase IIIb study published in the New England Journal of Medicine found that esketamine nasal spray achieved higher remission rates (27.1%) compared to quetiapine extended-release (17.6%) in patients with treatment-resistant depression, indicating its potential as a targeted therapy for this population.
A new study reveals that esketamine nasal spray is effective in treating treatment-resistant depression, with 27.1% of patients achieving remission after 8 weeks compared to 17.6% on quetiapine XR. Long-term data shows sustained remission rates at 21.7% for esketamine NS and 14.1% for quetiapine XR.
Researchers at Northwestern University developed Lattice, a device that simulates human disease in multiple organs to analyze interactions and test new drugs. The technology can replicate complex disease processes, allowing scientists to study the effects of obesity on endometrial cancer, for example.
Armida Labs, a UCR-founded pharmaceutical company, has received a $400,000 NIH Small Business Innovation Research grant to develop its breakthrough pancreatic cancer therapy Targefrin. The grant will enable the company to gather industry-standard data for human clinical trials.
Men with metastatic prostate cancer in Sweden experienced an average survival rate increase of six months after dual treatment was introduced from 2016 onwards. This improvement coincides with the gradual rollout of 'dual treatment', combining standard hormone therapy and chemotherapy or androgen receptor blockers.
Researchers found that MDMA increased feelings of connection and oxytocin levels in volunteers, while methamphetamine also showed similar effects. These findings suggest potential therapeutic benefits for traditional talk therapy.
Researchers at UVA Health System have developed a powerful new tool to understand how medications affect men and women differently. The model has provided unprecedented insights into biological processes in the liver, helping ensure that new medications will not cause harmful side effects.
A new editorial paper highlights the importance of including older patients in lung cancer clinical trials, where they are often undertreated due to age-related factors. The paper emphasizes the need for increased collaboration among stakeholders to enhance enrollment and retention of older cancer patients.
Researchers found that etripamil nasal spray restored normal heart rhythms within 30 minutes in 54% of patients, making it a potential new option for self-treating paroxysmal supraventricular tachycardia. The study showed the medication to be safe and well-tolerated.
A significant increase in the need for treatment of eye diseases is expected due to the growing elderly population. The number of patients requiring anti-VEGF medication is projected to rise by 50% over the next five years.
Researchers developed a computational model to analyze glucose-responsive insulin (GRI) performance in human patients. The model predicted that differences in sugar receptor behavior between humans and lab animals led to the drug's poor effect in clinical trials. This breakthrough helps researchers design better GRIs, potentially reduc...
A new health care utility model called Civica Rx increases supply security and reduces costs for health systems, with increased access to critical medications. The model prioritizes access over profit and offers transparent pricing for all customers.
A clinical trial has shown that methotrexate is a useful and safe treatment for children with severe atopic dermatitis, offering better objective disease control compared to ciclosporin. The study found no concerning safety signals, making methotrexate an attractive alternative for patients in settings where healthcare resources are li...
Researchers found that patients prescribed amoxicillin-clavulanate had higher rates of gastrointestinal symptoms and yeast infections than those prescribed amoxicillin. The study showed no difference in treatment failure rates between the two antibiotics, with treatment failure occurring in less than 2% of cases.
A large international study led by Danish researchers may have brought us closer to a cure for HIV. The study found that patients who received monoclonal antibodies before pausing their regular treatment experienced a period of virus suppression, and some even saw their immune system partially or completely suppress the virus.
Philip Low, a Purdue University researcher, is working on validating a previously successful malaria treatment by reducing the number of days required for therapy. His goal is to prevent drug-resistant strains from proliferating and save lives in developing countries.
Patients with stage 1-3 non-small cell lung cancer treated with combination immunotherapy before surgery had a better major pathological response rate than those receiving single-agent therapy alone. The NeoCOAST platform trial found that targeting multiple cancer pathways through therapy may be superior to a single treatment.
Researchers discuss new drugs available for HER2-positive breast cancer patients with brain metastasis, showing improved outcomes and quality of life. The development of targeted therapies has led to better survival rates among these patients.
The collaboration has garnered $5.68 million of grant support, with a five-year $2.13 million National Institutes of Health R01 grant and a five-year $2.89 million NIH R01 grant. Researchers are using computational biology to model a key Alzheimer's protein called TREM2 and its interactions with small chemical molecules.
A new computational approach removes movement in heart cell and tissue images, allowing direct monitoring of electro-mechanical coupling. The algorithm mimics a drug's action, giving insight into heart diseases.
Researchers at Pritzker Molecular Engineering have developed an 'inverse vaccine' that can eliminate autoimmune reactions associated with multiple sclerosis, type 1 diabetes, and rheumatoid arthritis. The vaccine works by removing the immune system's memory of a molecule, allowing it to tolerate healthy tissues.
Researchers at University of Tsukuba found that aripiprazole modulates the mammalian central circadian clock by disrupting synchronization among clock neurons and enhancing responsiveness to light stimuli in mice. This discovery expands the potential clinical usage of aripiprazole as a treatment for circadian rhythm sleep disorders.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Researchers have developed a device that can be implanted into tumors during surgery to test new treatments, providing unprecedented insight into the effects of drugs on glioma tumors. The device, which is designed to be used during standard of care surgery, caused no adverse effects on patients in a phase 1 clinical trial.
Johns Hopkins Medicine will improve clinical trial efficiency and quality with a $24.5M grant, reducing startup time by up to 50% and enhancing participant engagement. The Trial Innovation Center will develop new methods for multicenter trials, including AI-enhanced patient screening and gamification.
A new opinion piece highlights the safety gap in clinical trials and drug labeling for people with obesity, arguing that correct dosing instructions should be included on labels. The authors recommend a three-pronged approach to address this gap, including conducting studies in people with obesity before market approval.